The Vanguard Group Discloses Interests in Avadel Pharmaceuticals

The Vanguard Group, Inc. has released a Form 8.3 disclosure concerning its interests in Avadel Pharmaceuticals plc. As of November 5, 2025, Vanguard held 5,523,344 shares of US$0.01 ordinary stock, representing a 5.67% stake in the company. This positions Vanguard as a significant shareholder in Avadel Pharmaceuticals, as required by the Irish Takeover Panel Act of 1997, Rule 8.3.

The disclosure also reports minor transactions, including the purchase of 190 shares and sale of 514 shares at a consistent price of $18.96 per share. There are no noted positions in cash or stock-settled derivatives. Furthermore, Vanguard confirmed the absence of any indemnity, option arrangement, or agreements influencing dealing strategies.

Vanguard made no additional disclosures with respect to other associated parties within the offer, emphasizing a concentrated focus solely on Avadel Pharmaceuticals.